Sign in
TerminatedPhase 2

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Key facts

Who runs it
Sun Yat-sen University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 2
People taking part
25 people enrolled
Started
21 Mar 2022
Ended
21 Jul 2025
Type of study
Interventional
Treatments tested
  • Deferoxamine Plus Chemotherapy
Record updated
22 July 2025
Why it stopped
Difficulty accruing subjects the study accrual was closed.

Who can take part

Age
18 years to 70 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Has measurable metastatic triple-negative breast cancer, with at least 1 measurable lesion per RECIST criteria
  • Fail second-line or above anti-tumor treatment
  • Evaluation is stable disease with a trend of progression
  • Minimum life expectancy 16 weeks
  • Histological confirmation of breast cancer on primary tumour at diagnosis/on biopsy of metastasis
  • ECOG Performance Status (PS) 0-2 with no deterioration over previous 2 weeks
  • Normal organ function
  • Has signed a Patient Informed Consent Form

Who cannot take part

  • With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment
  • Inability or unwillingness to comply with study procedures, including inability to take regular oral medication
  • Patients with severe liver and kidney insufficiency
  • Deferoxamine Ingredients allergy
  • Eastern Cooperative Oncology Group (ECOG) score of ≥ 2
  • Researchers consider it is not suitable for participation

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The objective of the study is to evaluate the efficacy and safety of chemotherapy plus deferoxamine in metastatic breast cancer whose evaluation is stable disease with a trend of progression.

The group in the trial

  • Treatment armTreatment being tested

    Deferoxamine:50mg/kg+500ml normal saline (NS) plus chemotherapy

    Treatment: Deferoxamine Plus Chemotherapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer: A Single-armed, Phase II Trial
Record updated
22 July 2025